Dublin, Feb. 25, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/zmzmmz/artificial_tears) has announced the addition of the "Artificial Tears - Global Strategic Analysis" report to their offering.
This report analyzes the worldwide markets for Artificial Tears in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.
Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
The report profiles 68 companies including many key and niche players such as:
- Abbott Medical Optics Inc. (US)
- Allergan, Inc. (US)
- Akorn, Inc. (US)
- Bausch & Lomb Incorporated. (US)
- Johnson & Johnson (US)
- Novartis International AG (Switzerland)
- Alcon, Inc. (Switzerland)
- Santen Pharmaceuticals Co, Ltd. (Japan)
- Novagali Pharma S.A. (France)
Key Topics Covered:
1. Industry Overview
2. Noteworthy Market Trends
3. Dry Eye Syndrome
4. Product Overview
5. Product Launches/Approvals/ Introductions
6. Recent Industry Activity
7. Focus On Select Global Players
8. Global Market Perspective
Total Companies Profiled: 68 (including Divisions/Subsidiaries 74)
- The United States (25)
- Canada (3)
- Japan (4)
- Europe (22)
- - France (3)
- - Germany (3)
- - The United Kingdom (5)
- - Italy (1)
- - Spain (1)
- - Rest of Europe (9)
- Asia-Pacific (Excluding Japan) (17)
- Africa (2)
- Middle-East (1)
For more information visit http://www.researchandmarkets.com/research/zmzmmz/artificial_tears
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals, Optical


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Washington Post Publisher Will Lewis Steps Down After Layoffs
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



